- Home
- CXDO vs KYTX Comparison
CXDO vs KYTX Comparison
Compare CXDO & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXDO
- KYTX
- Stock Information
- Founded
- CXDO 1995
- KYTX 2018
- Country
- CXDO United States
- KYTX United States
- Employees
- CXDO N/A
- KYTX N/A
- Industry
- CXDO Telecommunications Equipment
- KYTX
- Sector
- CXDO Telecommunications
- KYTX
- Exchange
- CXDO Nasdaq
- KYTX NYSE
- Market Cap
- CXDO 139.6M
- KYTX 166.4M
- IPO Year
- CXDO 1998
- KYTX 2024
- Fundamental
- Price
- CXDO $5.35
- KYTX $3.33
- Analyst Decision
- CXDO Strong Buy
- KYTX Buy
- Analyst Count
- CXDO 2
- KYTX 5
- Target Price
- CXDO $6.50
- KYTX $23.20
- AVG Volume (30 Days)
- CXDO 124.6K
- KYTX 325.4K
- Earning Date
- CXDO 03-04-2025
- KYTX 02-12-2025
- Dividend Yield
- CXDO N/A
- KYTX N/A
- EPS Growth
- CXDO N/A
- KYTX N/A
- EPS
- CXDO 0.05
- KYTX N/A
- Revenue
- CXDO $58,762,000.00
- KYTX N/A
- Revenue This Year
- CXDO $15.59
- KYTX N/A
- Revenue Next Year
- CXDO $10.49
- KYTX N/A
- P/E Ratio
- CXDO $115.07
- KYTX N/A
- Revenue Growth
- CXDO 16.41
- KYTX N/A
- 52 Week Low
- CXDO $2.92
- KYTX $3.24
- 52 Week High
- CXDO $7.59
- KYTX $30.60
- Technical
- Relative Strength Index (RSI)
- CXDO 50.97
- KYTX 36.40
- Support Level
- CXDO $5.05
- KYTX $3.24
- Resistance Level
- CXDO $5.50
- KYTX $3.47
- Average True Range (ATR)
- CXDO 0.26
- KYTX 0.28
- MACD
- CXDO -0.02
- KYTX -0.02
- Stochastic Oscillator
- CXDO 31.25
- KYTX 8.82
About CXDO Crexendo Inc.
Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of revenue from the Cloud telecommunications segment.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.